Proteomic Analysis of Anticancer TCMs Targeted at Mitochondria

Table 3

Summary of proteomics-based studies of paclitaxel resistance in various cancers.

Treatments	Proteomics methods	Cancer types	Cellular models	References
Paclitaxel-sensitive A549 versus paclitaxel-resistant A549	2-DE DIGE	Non-small-cell lung carcinoma	A549	[35]
Untreated versus paclitaxel versus MEK inhibitor versus paclitaxel + MEK inhibitor	2-DE	Non-small-cell lung carcinoma	H157	[30]
Untreated versus paclitaxel treated	2-DE DIGE	Breast cancer	MDA-MB-435S	[106]
Untreated versus paclitaxel treated	2-DE	Cervical cancer	Hela	[107]
Untreated versus paclitaxel treated	2-DE DIGE	Promyeloid leukaemia	HL-60	[108]
Untreated versus paclitaxel treated	2-DE	Dermal papilla	Dermal papilla	[109]
Paclitaxel-sensitive CaOV3 versus paclitaxel-resistant variant CaOV3	N/A	Ovarian cancer	CaOV3 and OV90	[32]
SK-BR-3 versus paclitaxel-resistant SK-BR-3	2-DE	Breast cancer	SK-BR-3	[34]

N/A: not applicable.